Key Highlights:
- Dr. Reddy’s Laboratories has launched Hevaxin, a vaccine designed to prevent infection caused by Hepatitis E in adults aged 18–65 years in India.
- The vaccine has been approved by the Drug Controller General of India and is currently the only vaccine available in India for active immunisation against Hepatitis E. Clinical studies indicate that it provides protective immunity with a favourable safety and tolerability profile.
- According to the World Health Organization, Hepatitis E affects around 20 million people globally each year. In India, it accounts for up to 40% of acute hepatitis cases, highlighting the need for preventive options such as Hevaxin to reduce disease burden and support public health initiatives.
Implications:
Dr. Reddy’s grabs monopoly control over Hepatitis E prevention, dominating public health tenders and private vaccination drives as awareness explodes.
Vaccine breakthrough catapults them into national immunization leadership, crushing import dependence while unlocking combo viral hepatitis platforms.
Source: Expresspharma | Image: Dr. Reddy
No Comment! Be the first one.